Takeda expands COVID-19 vaccine supply in Japan through partnership with Moderna and Government of Japan

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan's Ministry of Health Labour and Welfare (MHLW).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Takeda Business and Industry Source Type: news